The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO)

NCT ID: NCT02166424

Last Updated: 2017-12-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study aims to examine the efficacy and safety of omega-3 polyunsaturated fatty acids for pregnant women with depressive symptoms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Maternal depression can have a significant harmful influence on both mothers and children. Considering the possibility of adverse effects of antidepressants and previous meta-analyses showing the positive effects of omega-3 polyunsaturated fatty acids (PUFAs) supplementation in reducing depressive symptoms, omega-3 PUFAs may provide a safe strategy. The investigators evaluate efficacy and safety of omega-3 PUFAs for pregnant women with depressive symptoms. (Participants who skipped taking supplements for more than 7 days will be excluded from a per protocol analysis.)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy Depression

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Pregnancy Depression omega-3 fatty acids

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Omega-3 polyunsaturated fatty acids

1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily

Group Type ACTIVE_COMPARATOR

Omega-3 polyunsaturated fatty acids

Intervention Type DIETARY_SUPPLEMENT

olive oil

2880mg olive oil daily

Group Type PLACEBO_COMPARATOR

Olive oil

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omega-3 polyunsaturated fatty acids

Intervention Type DIETARY_SUPPLEMENT

Olive oil

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

1200mg EPA and 600mg DHA daily 2880mg olive oil daily

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. pregnant women aged 20 years or older
2. between 12-24 weeks gestation
3. a Japanese conversational ability in Japan site or a Mandarin conversational ability in Taiwan site to understand the scope of the present trial and to provide written consent for study participation
4. planned to take assessments after childbirth
5. an Edinburgh Postnatal Depression Scale (EPDS) score is 9 or more
6. to have good physical health judged by obstetricians.

Exclusion Criteria

1. history and current suspicion of psychosis or bipolar I disorder or substance-related disorder or eating disorder or personality disorder
2. Serious psychiatric symptoms such as self-harm behavior or in need of rapid psychiatric treatment
3. difficult to expect a normal birth (ex: fetal malformation etc.)
4. having a history of bleeding disorder such as von Willebrand's Disease
5. regular treatment with aspirin or warfarin within the last 3 months
6. a smoking habit of ≥40 cigarettes per day
7. regular treatment with ethyl icosapentate or regular consumption of omega-3 PUFA supplements within the last 3 months
8. a habit of eating fish as a main dish ≥4 times per week.
Minimum Eligible Age

20 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

China Medical University, Taiwan

OTHER

Sponsor Role collaborator

Japan Society for the Promotion of Science (JSPS)

UNKNOWN

Sponsor Role collaborator

University of Toyama

OTHER

Sponsor Role collaborator

Chiba University

OTHER

Sponsor Role collaborator

National Center for Child Health and Development

UNKNOWN

Sponsor Role collaborator

Tokyo Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Daisuke Nishi

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daisuke Nishi, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Tokyo Medical University

Kuan-Pin Su, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

China Medical Univeristy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Toda Chuo Women's Hospital

Toda, Saitama, Japan

Site Status

National Center for Child Health and Development

Setagaya City, Tokyo, Japan

Site Status

Tokyo Medical University

Shinjyuku-ku, Tokyo, Japan

Site Status

China Medical University

Taichung, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan Taiwan

References

Explore related publications, articles, or registry entries linked to this study.

Nishi D, Su KP, Usuda K, Chiang YJ, Guu TW, Hamazaki K, Nakaya N, Sone T, Sano Y, Tachibana Y, Ito H, Isaka K, Hashimoto K, Hamazaki T, Matsuoka YJ. The synchronized trial on expectant mothers with depressive symptoms by omega-3 PUFAs (SYNCHRO): Study protocol for a randomized controlled trial. BMC Psychiatry. 2016 Sep 15;16(1):321. doi: 10.1186/s12888-016-1031-2.

Reference Type DERIVED
PMID: 27630014 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SYNCHRO-RCT

Identifier Type: -

Identifier Source: org_study_id